Αποτελέσματα Αναζήτησης
Find the latest news and updates on Inovio Pharmaceuticals, a biotechnology company developing DNA medicines for HPV, cancer, and infectious diseases. See press releases, earnings reports, stock performance, and more.
- Profile
See the company profile for Inovio Pharmaceuticals, Inc....
- Sustainability
See Inovio Pharmaceuticals, Inc. (INO) Environment, Social...
- Options Chain
View the basic INO option chain and compare options of...
- Statistics
Find out all the key statistics for Inovio Pharmaceuticals,...
- Financials
Get the detailed quarterly/annual income statement for...
- INO
Find the latest Inovio Pharmaceuticals, Inc. (INO) stock...
- Profile
INOVIO is a clinical-stage biotechnology company developing DNA medicines and vaccines using proprietary technology and delivery devices. Learn about its pipeline, leadership, and latest news on its website.
Find the latest Inovio Pharmaceuticals, Inc. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing.
21 Οκτ 2024 · About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
10 Οκτ 2023 · Updated Cash Guidance. INOVIO previously announced it expected its cash runway to fund the company's operations into the third quarter of 2025. The changes to the development plan for INO-3107 as a result of the FDA feedback announced today could affect that prior guidance.
9 Νοε 2021 · Inovio, a biotechnology company developing DNA medicines, can proceed with the INNOVATE Phase 3 segment of its COVID-19 vaccine candidate, INO-4800, in the U.S. The vaccine is stable at room temperature and has a five-year shelf life.
7 Σεπ 2023 · INOVIO's DNA medicines in development are delivered using its investigational proprietary device, CELLECTRA ®, to produce immune responses against targeted pathogens and cancers. For more ...
